Basilea Pharmaceutica (CH:BSLN)
:BSLN
Top Page
Basilea Pharmaceutica
(BSLN)
Select Model
Select Model
Rating:71Outperform
Price Target:
CHF59.00
▲(12.17% Upside)
Action:ReiteratedDate:02/25/26
The score is driven primarily by strong financial performance (high margins, accelerating revenue, and solid cash generation) and a constructive earnings outlook with improving balance-sheet position and identifiable pipeline catalysts. These positives are tempered by weak near-term technical momentum and medium-term risks flagged on the call (loss of exclusivity timing, higher R&D spend, and partner/clinical execution uncertainty), while valuation appears reasonable rather than deeply discounted.
Positive Factors
Strong cash generation
Consistent operating and free cash flow levels provide durable internal funding for operations and clinical programs, reducing near-term financing needs. Strong cash balances and positive cash conversion enhance financial flexibility to fund Phase III studies and commercialization over the next several years.
Negative Factors
Loss of exclusivity risk for Cresemba
Cresemba is a major cash engine; anticipated generic entry within 2–3 years creates structural revenue pressure. Management will need successful Phase III outcomes and commercialization of pipeline assets to replace cash flow, making future growth contingent on execution and new product launches.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Consistent operating and free cash flow levels provide durable internal funding for operations and clinical programs, reducing near-term financing needs. Strong cash balances and positive cash conversion enhance financial flexibility to fund Phase III studies and commercialization over the next several years.
Read all positive factors
Basilea Pharmaceutica (BSLN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF629.86M
Dividend YieldN/A
Average Volume (3M)41.01K
Price to Earnings (P/E)16.6
Beta (1Y)0.94
Revenue Growth58.51%
EPS GrowthN/A
CountryCH
Employees164
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.54
Shares Outstanding13,320,867
10 Day Avg. Volume32,790
30 Day Avg. Volume41,007
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)5.22
Price to Sales (P/S)2.88
P/FCF Ratio11.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF69.00Price Target Upside31.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)4.35
Revenue Forecast (FY)CHF253.01M
Basilea Pharmaceutica Business Overview & Revenue Model
Company Description
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azo...
How the Company Makes Money
Basilea Pharmaceutica generates revenue primarily through the commercialization of its pharmaceutical products, including sales of its approved drugs and potential royalties from product licensing agreements. The company also engages in strategic ...
Basilea Pharmaceutica Earnings Call Summary
Earnings Call Date:Feb 17, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Positive
The call communicated a strong operational and financial year with multiple positive metrics (robust revenue growth, rising royalties, improved cash position, debt reduction, substantial nondilutive funding, successful U.S. launch of Zevtera, and a strengthened Phase III pipeline). Key near-term challenges include higher R&D spending, expected shifts in revenue mix from product supply transitions, and the medium-term impact of Cresemba loss of exclusivity (U.S. generics from Q4 2027; Europe H2 2028) which will require successful execution of the Phase III programs to sustain growth. Overall, the balance of accomplishments, financial resilience and visible pipeline catalysts outweigh the outlined risks, contingent on clinical and partner execution.Positive Updates
Strong Cresemba Growth and Market Leadership
Cresemba global in-market sales increased 27% year-on-year to USD 693 million (12 months to Sep 2025). Growth is strong in established markets with China and Japan moving beyond launch phase, and Cresemba is now the global market leader by value.
Negative Updates
Rising R&D Investment Pressure
Research & development expenses are expected to increase by approximately 20% in 2026 as the company funds two ongoing fosmanogepix Phase III studies, prepares for ceftibuten-ledaborbactam Phase III, and starts a new Phase I with BAL2420. Operating expenses in 2025 were CHF 141.5 million, reflecting increased R&D spend.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Cresemba Growth and Market Leadership
Cresemba global in-market sales increased 27% year-on-year to USD 693 million (12 months to Sep 2025). Growth is strong in established markets with China and Japan moving beyond launch phase, and Cresemba is now the global market leader by value.
Read all positive updates
Company Guidance
Basilea guided 2026 Cresemba- and Zevtera-related revenue of around CHF 200 million, expecting total revenue to rise by ~10%, R&D expenses to increase by ~20% and operating profit to grow disproportionately by about 20%; they also forecast the cash contribution from the commercial business to increase from CHF 155 million in 2025 to CHF 170 million in 2026. For context they reported 2025 results of total revenue CHF 232.4m (+11.4% y/y), Cresemba in‑market sales USD 693m for the 12 months to Sept 2025 (+27% y/y), royalties CHF 111.6m (+15.4% y/y), milestone/upfronts CHF 32m, other revenues CHF 38m, cost of goods sold CHF 39.3m, operating expenses CHF 141.5m, operating profit CHF 51.5m, net profit CHF 40.2m, cash and equivalents CHF 162.3m (up 30%) and net cash CHF 86.9m after convertible debt of CHF 76m (debt reduced by CHF 145m since Jan 2022, incl. CHF 21m in the period). Longer‑term guidance included ~CHF 600m cumulative cash flow from Cresemba and Zevtera over 2026–2030, >USD 430m of nondilutive R&D funding awarded (with >USD100m committed and ~USD330m still potentially available), USD 70m secured in 2025, expected timing of Cresemba generic impact from Q4 2027 (US) and H2 2028 (Europe) with full‑year visibility in 2029, and product milestones with fosmanogepix targeted to enter the market in early 2029 and ceftibuten‑ledaborbactam about a year later.Basilea Pharmaceutica Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
64
Positive
Cash Flow
82
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 232.40M | 208.54M | 157.63M | 147.76M | 148.12M |
| Gross Profit | 193.10M | 169.86M | 130.84M | 120.96M | 124.05M |
| EBITDA | 51.60M | 63.13M | 23.18M | 26.21M | 6.72M |
| Net Income | 40.20M | 77.59M | 10.45M | 12.15M | -6.83M |
Balance Sheet | |||||
| Total Assets | 282.00M | 257.76M | 173.29M | 220.85M | 247.27M |
| Cash, Cash Equivalents and Short-Term Investments | 162.34M | 120.71M | 59.90M | 84.70M | 148.70M |
| Total Debt | 100.93M | 111.67M | 128.61M | 187.14M | 218.96M |
| Total Liabilities | 154.06M | 176.76M | 183.29M | 241.56M | 305.87M |
| Stockholders Equity | 127.94M | 81.00M | -10.00M | -20.71M | -58.61M |
Cash Flow | |||||
| Free Cash Flow | 59.47M | 72.65M | 13.21M | 3.75M | -32.88M |
| Operating Cash Flow | 62.09M | 74.36M | 14.24M | 7.06M | -32.02M |
| Investing Cash Flow | -2.86M | -1.01M | -1.03M | 91.65M | 3.58M |
| Financing Cash Flow | -21.43M | -13.16M | -57.30M | -45.25M | 16.64M |
Basilea Pharmaceutica Technical Analysis
Negative
52.60
Price Trends
54.32
Negative
52.25
Negative
50.84
Positive
Market Momentum
-0.91
Positive
41.31
Neutral
47.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BSLN, the sentiment is Negative. The current price of 52.6 is below the 20-day moving average (MA) of 52.74, below the 50-day MA of 54.32, and above the 200-day MA of 50.84, indicating a neutral trend. The MACD of -0.91 indicates Positive momentum. The RSI at 41.31 is Neutral, neither overbought nor oversold. The STOCH value of 47.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:BSLN.
Basilea Pharmaceutica Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF629.86M | 16.63 | ― | ― | 58.51% | ― | |
56 Neutral | CHF894.85M | 498.59 | -7.82% | ― | 104.01% | 33.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | CHF304.43M | -38.37 | ― | ― | 744.64% | ― | |
48 Neutral | CHF216.96M | -0.98 | -301.13% | ― | -56.85% | -186.55% | |
45 Neutral | CHF135.26M | -2.50 | -51.05% | ― | -100.00% | 14.45% | |
45 Neutral | CHF794.46M | -8.17 | ― | ― | 229.23% | 63.47% |
* Healthcare Sector Average
CH:BSLN
Basilea Pharmaceutica
51.20
4.40
9.40%
CH:MOLN
Molecular Partners AG
3.35
-0.52
-13.44%
CH:IDIA
Idorsia Ltd
3.13
2.05
190.35%
CH:KURN
Kuros Biosciences
22.84
3.56
18.46%
CH:NWRN
Newron Pharmaceuticals SpA
14.64
6.54
80.74%
CH:SANN
Santhera Pharmaceuticals Holding
15.46
0.40
2.66%
Basilea Pharmaceutica Corporate Events
Basilea Wins BARDA Funding to Advance Novel Oral Antibiotic for Drug-Resistant UTIs
Feb 25, 2026
Basilea Pharmaceutica has secured USD 6 million in funding from the U.S. Biomedical Advanced Research and Development Authority to advance its novel oral antibiotic combination Ceftibuten-Ledaborbactam Etzadroxil for complicated urinary tract infe...
Basilea boosts revenues, triples net cash as anti‑infective pipeline advances
Feb 17, 2026
Basilea Pharmaceutica reported 2025 total revenue of CHF 232.4 million, up 11.4%, driven by a 15.4% rise in license income and strong demand for Cresemba, alongside higher BARDA‑ and CARB‑X‑related contract revenues. Despite incr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.